Related Experiment Video
Updated: Jul 10, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Recent advances in clinical oncoproteomics.
1Jain PharmaBiotech, Basel, Switzerland. jain@pharmabiotech.ch
Summary
Oncoproteomics applies protein analysis to cancer research, aiding in biomarker discovery, diagnosis, and personalized treatment. Integrated with other "-omics" approaches, it enhances understanding of cancer pathology and drug resistance.
Area of Science:
- Oncoproteomics, the application of proteomic technologies in cancer research.
Background:
- Proteomic technologies have advanced significantly, improving understanding of cancer's pathological mechanisms.
- Proteomics aids in discovering cancer biomarkers, diagnosis, and personalized treatment strategies.
Purpose of the Study:
- To review the progress and applications of oncoproteomics in cancer research.
- To highlight the role of proteomics in understanding cancer and developing targeted therapies.
Main Methods:
- Protein identification from blood or tumor tissue using laser capture microdissection (LCM) and tissue microarrays.
- Utilizing protein biochips for cancer diagnosis and clinical trial monitoring.
- Integrating nanobiotechnology to refine proteomic protocols for improved protein analysis.
Main Results:
- Proteomics contributes to understanding tumor invasiveness and drug resistance.
- Oncoproteomics has been applied to various cancers, including brain, breast, colon, prostate, and leukemia.
- Nanoproteomics enhances sensitivity and efficiency in identifying protein traces.
Conclusions:
- Proteomics is crucial for advancing cancer diagnosis and developing personalized cancer treatments.
- Integrated multi-omics approaches are necessary for a comprehensive understanding of cancer.
- Continued refinement of proteomic technologies will further impact clinical oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...